A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07185997

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:29:09.492277+00:00

Published At

2026-04-16T00:00:00+00:00

Record Updated At

2026-04-16

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-Small-Cell Lung Cancer", "Metastatic Non-Small-Cell Lung Cancer", "Advanced Non-Small-Cell Lung Cancer", "EGFR P-Loop and Alpha C-Helix Compressing", "EGFR PACC", "EGFR Uncommon Mutations"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-16"

protocolSection.identificationModule.nctId

"NCT07185997"

protocolSection.identificationModule.officialTitle

"A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator\u0027s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Non-Small-Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Metastatic Non-Small-Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Advanced Non-Small-Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• EGFR P-Loop and Alpha C-Helix Compressing (protocolSection.conditionsModule.conditions)
• EGFR PACC (protocolSection.conditionsModule.conditions)
• EGFR Uncommon Mutations (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.